<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02654470</url>
  </required_header>
  <id_info>
    <org_study_id>FLXibility</org_study_id>
    <nct_id>NCT02654470</nct_id>
  </id_info>
  <brief_title>Watchman FLX Left Atrial Appendage Closure Device Post Approval Study ( Europe Only)</brief_title>
  <official_title>Watchman FLX Left Atrial Appendage Closure Device Post Approval Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boston Scientific Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Premier Research Group plc</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Iqvia Pty Ltd</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Boston Scientific Corporation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Watchman FLX Left Atrial Appendage Closure Device Post Approval Study
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      WATCHMAN FLX is intended to prevent thrombus embolization from the left atrial appendage and
      reduce the risk of life-threatening bleeding events in patients with non-valvular atrial
      fibrillation who are eligible for anticoagulation therapy or who have a contraindication to
      anticoagulation therapy.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 16, 2019</start_date>
  <completion_date type="Anticipated">July 2021</completion_date>
  <primary_completion_date type="Anticipated">July 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>procedural success</measure>
    <time_frame>7 days post-implant</time_frame>
    <description>per Munich consensus paper (percentage)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>incidence of stroke, leak, thrombus and death</measure>
    <time_frame>1 year</time_frame>
    <description>per Munich consensus paper (rate per 100 PY)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>procedural complications</measure>
    <time_frame>7-days post implant</time_frame>
    <description>per Munich consensus paper (percentage)</description>
  </primary_outcome>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Non-valvular Atrial Fibrillation</condition>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Watchman FLX</intervention_name>
    <description>Patients who are receiving the Watchman FLX device</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        All subjects who meet all inclusion and no exclusion criteria can be enrolled. A subject
        who signs informed consent is considered enrolled in the study. The subjects selected for
        participation will be from the investigator's general patient population.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Subjects who are eligible for a WATCHMAN FLX device according to current international
             and local guidelines and currently approved indications;

          2. Subject who are willing and capable of providing informed consent and participating in
             all testing associated with this clinical investigation at an approved clinical
             investigational centre;

          3. Subjects whose age is 18 years or above, or of legal age to give informed consent
             specific to state and national law.

        Exclusion Criteria:

          1. Subjects who are currently enrolled in another investigational study or registry that
             would directly interfere with the current study, except when the Subject is
             participating in a mandatory governmental registry, or a purely observational registry
             with no associated treatments. Each instance should be brought to the attention of the
             sponsor to determine eligibility

          2. The subject is unable or not willing to complete follow-up visits and examinations for
             the duration of the study

          3. Women of childbearing potential who are, or plan to become, pregnant during the time
             of the study (method of assessment upon physician's discretion);

          4. Documented life expectancy of less than 12 months.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Timothy Betts</last_name>
    <role>Principal Investigator</role>
    <affiliation>John Radcliffe Hospital, Oxford, UK</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Raffaella Falciglia</last_name>
    <phone>+410216510160</phone>
    <email>raffaella.falciglia@bsci.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Elisa Vireca, MS</last_name>
    <phone>+3224167011</phone>
    <email>elisa.vireca@bsci.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Aarhus University Hospital</name>
      <address>
        <city>Aarhus</city>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jens Erik Nielsen Kudsk</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Rigshospitalet Copenhagen</name>
      <address>
        <city>Copenhagen</city>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Hospices Civils de Lyon</name>
      <address>
        <city>Lyon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gilles Rioufol</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hopital Prive Jacques Cartier</name>
      <address>
        <city>Massy</city>
        <country>France</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Elisabeth Krankenhaus</name>
      <address>
        <city>Essen</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thomas Schmitz</last_name>
    </contact>
    <investigator>
      <last_name>Thomas Schmitz</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cardio Vasculares Centrum Sankt Katharinen</name>
      <address>
        <city>Frankfurt</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Horst Sievert</last_name>
    </contact>
    <investigator>
      <last_name>Horst Sievert</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cardioangiologisches Centrum Bethanien</name>
      <address>
        <city>Frankfurt</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Boris Schmidt</last_name>
    </contact>
    <investigator>
      <last_name>Boris Schmidt</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cardiologicum Hamburg</name>
      <address>
        <city>Hamburg</city>
        <zip>22041</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Martin W Bergmann, Prof. Dr.</last_name>
    </contact>
    <investigator>
      <last_name>Martin W Bergmann</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Uni Jena</name>
      <address>
        <city>Jena</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sven Moebius-Winkler</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Herzzentrum Universit√§t Leipzig</name>
      <address>
        <city>Leipzig</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marcus Sandri</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Beaumont Hospital</name>
      <address>
        <city>Dublin</city>
        <country>Ireland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Foley</last_name>
    </contact>
    <investigator>
      <last_name>David Foley</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ospedale San Raffaele</name>
      <address>
        <city>Milan</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patrizio Mazzone</last_name>
    </contact>
    <investigator>
      <last_name>Patrizio Mazzone</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ospedale San Francesco</name>
      <address>
        <city>Nuoro</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gavino Casu</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>A.O. Umberto I</name>
      <address>
        <city>Siracusa</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>St. Antonius Hospital</name>
      <address>
        <city>Nieuwegein</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lucas Boersma</last_name>
    </contact>
    <investigator>
      <last_name>Lucas Boersma</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Gornoslaskie Centrum Medyczne im. prof. Leszka Gieca Slaskiego Uniwersytetu Medycznego w Katowicach</name>
      <address>
        <city>Katowice</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Clinical Hospital University of Medicine</name>
      <address>
        <city>Poznan</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marek Grygier</last_name>
    </contact>
    <investigator>
      <last_name>Marek Grygier</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital De La Santa Creu I Sant Pau</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dabit Arzamendi</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Virgen Macarena</name>
      <address>
        <city>Sevilla</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rafael Salmeron</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Royal Sussex County Hospital</name>
      <address>
        <city>Brighton</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Hildick-Smith</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>John Radcliffe Hospital</name>
      <address>
        <city>Oxford</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tim Betts</last_name>
    </contact>
    <investigator>
      <last_name>Tim Betts</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Denmark</country>
    <country>France</country>
    <country>Germany</country>
    <country>Ireland</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>Poland</country>
    <country>Spain</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>January 11, 2016</study_first_submitted>
  <study_first_submitted_qc>January 11, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 13, 2016</study_first_posted>
  <last_update_submitted>July 8, 2020</last_update_submitted>
  <last_update_submitted_qc>July 8, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 9, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

